Clinicians making treatment decisions generally refer to methodologically strong clinical trials examining the impact of therapy on patient-important outcomes such as morbid end points, ie, stroke, myocardial infarction, and death, or health-related quality of life end points. These trials require such a large sample size or long patient follow-up that researchers have proposed the alternative of substituting surrogate outcomes or end points for the target event, allowing shorter and smaller trials to be conducted. This offers an apparently simpler solution to the difficulty of conducting large or long-term trials. A surrogate outcome can be defined as an outcome that can be observed sooner, at lower cost, or less invasively than the true outcome, and that enables valid inferences about the effect of intervention on the true outcome. Surrogate outcomes or end points (also known as surrogate markers) have to be distinguished from biomarkers, although the two concepts are related. According to the Biomarker Definitions Working Group,¹ a biomarker is “a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic process, or pharmacologic responses to a therapeutic intervention.” According to the US Food and Drug Administration (FDA)² a “valid biomarker” is one “that is measured in an analytical test system with well-established performance characteristics and for which there is an established framework or body of evidence that elucidates the physiologic, toxicologic, pharmacologic or clinical significance of the test result.” Thus, in the drug development process, biomarkers can be useful tools from the discovery stage, where they are used to investigate pathophysiologic mechanisms related to...
either diagnosis or prognosis of a disease, through the later stages of clinical development. Biomarkers can be used in preclinical studies to confirm in vivo activity as well as to investigate dose-response relationships. During early clinical development programs (phase 1 and 2a), biomarkers are used to evaluate activity and to develop pharmacokinetic-pharmacodynamic relationships. In phase 3 and 4 studies, biomarkers are useful tools for stratifying study populations.

Surrogate outcomes are biomarkers that fit the following definition: “a biomarker that is intended to substitute for a clinical end point. A surrogate end point is expected to predict clinical benefit (or harm or lack of benefit or harm) based on epidemiologic, therapeutic, pathophysiologic, or other scientific evidence.” This definition of a surrogate outcome illustrates the key difference versus the role of the biomarker. A biomarker can be used as a surrogate outcome if it can reasonably predict a clinical benefit. Thus, although a surrogate outcome is by definition a biomarker, in fact, a very small minority of biomarkers meet the standard of a surrogate outcome. Before 1991, regulatory agencies such as the FDA used surrogate treatment outcomes in limited settings, mainly in the cardiovascular area. For example, antihypertensive drugs have been approved for marketing based on their effectiveness in lowering blood pressure, and cholesterol-lowering agents have been approved based on their ability to decrease serum cholesterol, not on the direct evidence that they decrease mortality from cardiovascular diseases. In 1991, during the acquired immune deficiency syndrome (AIDS) epidemic, surrogate outcomes were utilized for the first time as a viable path toward regulatory approval. Indeed, an important milestone was the use of CD4 cell count as a surrogate marker, because of its predictive value for outcome. This led to the approval of didanosine for the treatment of HIV. In 1992, the FDA formulated a new regulatory process, often referred to as “accelerated approval,” under which marketing approval can be provided for interventions that have been shown to have compelling effects on a validated surrogate treatment outcome.

At the present time, there are well-defined procedures in the FDA in which such approvals are routinely examined; for example, some anticancer treatments have been approved under the accelerated approval regulations. In these cases, drugs tested in patients refractory to available treatments are approved on the basis of their effects on tumor size, as assessed by imaging. The labeling adopted at the time of the approval indicates that the approval was based on the effects of the treatment on tumor size, without evidence of an effect on other clinical variables. It is only when subsequent studies demonstrate an effect on clinical outcome that the labeling is changed to include a description of the documented effect on survival.

In the field of drugs acting on the central nervous system (CNS), no treatments for neurologic or psychiatric diseases have been approved to date on the basis of an effect on a surrogate outcome. One obvious reason for this is the fact that no surrogate outcomes have been validated until now; this will be discussed in the next section.

**Surrogate outcome validation**

The presence of a correlation does not suffice to justify the replacement of a true clinical outcome by a surrogate marker of this outcome. Indeed, a surrogate outcome might not involve the same pathophysiologic process that results in the true clinical outcome. In oncology, an elevated level of a tumor marker such as prostate-specific antigen (PSA) in prostate cancer is the indication of an advanced tumor stage, and is clearly correlated with morbidity/mortality risks. However, PSA is not the mechanism through which the disease process influences the clinical outcome. It is thus questionable whether treatment-induced changes in this marker accurately predict treatment-induced effects on the clinical end points. General guidelines for the interpretation of clinical trials using surrogate outcomes have been proposed. In a recent paper, Fleming suggested a four-level hierarchy for outcome measures. *Level 1* is a true clinical efficacy measure, and includes those outcomes that directly reflect real benefits for the patient; for example, reducing the risk of stroke could be a surrogate for reducing the risk of death. *Level 2* is a validated surrogate outcome for a specific disease setting and class of intervention. This outcome, while not directly representing tangible clinical benefits, can be used to reliably predict the level of such benefits.
An example is blood pressure reduction as a surrogate risk for stroke, for a well-studied class of antihypertensive agents. 

Level 3 is a nonvalidated surrogate outcome, yet one established to be reasonably likely to predict clinical benefit for a specific disease setting and class of intervention. “Reasonably likely” implicates considerable clinical evidence that the effect of the intervention on the surrogate outcome measure (i) will accurately represent the effect of the intervention on what is thought to be the predominant mechanism through which the disease process induces tangible events; (ii) does not have important adverse effects on the clinical efficacy end point that would not be detected by the outcome measure; (iii) is consistent with the effects on the true clinical outcome; and (iv) is sufficiently strong and durable that it is reasonably likely to product meaningful clinical benefits on clinical efficacy measures. Illustrations of this level 3 of outcome measures would be a reduction in viral load to an undetectable level for 6 months in patients with advanced HIV infection.

Level 4 is a correlate outcome that is a measure of biological activity, but that has not been established to be at a higher level in this four-level hierarchy for outcome measures; biological markers, such as PSA, that almost certainly do not represent the biological mechanism through which the disease process induces clinically tangible events, would tend to be at level 4.

Marketing approval under the accelerated approval process can be provided for interventions having compelling effects on biological markers that are at least at level 3 in the hierarchy. In the field of drugs acting on the CNS, to date no compounds have been approved with the accelerated approval procedure on the basis of an effect on a surrogate outcome. This highlights the lack of strongly validated (ie, level 1, 2, or 3) surrogate outcomes in the field of neurology and psychiatry. The following sections will focus on definitions, applications, successes, and failures of biomarkers in Parkinson’s disease, affective disorder, and schizophrenia, although similar examples could be found for many other neurological or psychiatric disorders.

Neurology: Parkinson’s disease

Parkinson’s disease is a progressive neurodegenerative disorder characterized by rigidity, bradykinesia, postural instability, and tremor. Clinical decline reflects the ongoing degeneration of dopaminergic neurons. Development of specific biomarkers for Parkinson’s disease may be useful at the onset of neurodegeneration, the onset of disease, and/or to mark disease progression. At present, the most mature surrogate measures for Parkinson’s disease are based on the functional imaging of dopaminergic neurons with dopamine transporter ligands on the measures of dopamine metabolism with fluorodopa. 

2-β-Carbomethoxy-3-β-(4-[125I]iodophenyl)tropane (123I-b-CIT), a single photon-emission computed tomography (SPECT) radioligand that binds to the dopamine transporter on the presynaptic dopamine terminal,10 has been most extensively evaluated as a potential surrogate outcome in Parkinson’s disease. It has been reliably shown to distinguish healthy control subjects from parkinsonian patients.11 Moreover, longitudinal studies reveal an annual 6% to 10% reduction in striatal dopamine transporter as measured by 123I-b-CIT uptake in early Parkinson’s disease, with a slower decline in more advanced disease.9,12 However, the results of CALM-PD trial and the ELLDOPA trial contradicted these results. In the CALM-PD trial, subjects with early Parkinson’s disease requiring dopaminergic therapy were randomized to either initial pramipexole or initial levodopa.13 A subgroup of patients (n=28) were studied in terms of rate of striatal dopamine transporter loss as measured by SPECT 123I-b-CIT uptake.14 Results show that, over the course of 46 months, the pramipexole-treated patients showed a 16% decline in striatal uptake compared with 25% in the levodopa group. The biomarker advantage of pramipexole, however, did not translate into a clear, clinically meaningful advantage. Indeed, although patients on pramipexole had a lower incidence of complications, patients randomized to initial levodopa had an early and sustained improvement in function, and less somnolence and edema. In the ELLDOPA trial15 during which three increasing doses of levodopa were compared with placebo in patients with early Parkinson’s disease not requiring dopaminergic therapy, discordant results were noted between the clinical outcomes and the neuroimaging end point. Analysis of the 123I-b-CIT outcome suggested a trend toward a more rapid decline in striatal dopamine transporter in individuals on the highest doses of levodopa, but the largest clinical improvement was observed in the levodopa group, in the direction opposite to what would be predicted on the basis of the imaging marker. These results corroborate those of the CALM-PD trial, and indicate that the SPECT 123I-b-CIT...
biomarker advantage did not translate into a clinically meaningful advantage. Studies using \(^{18}\text{F}-\text{fluoro-L-dopa (F-dopa)}\) positron emission tomography (PET) as a surrogate outcome of Parkinson’s disease treatment show similar negative results. The accumulation of these radioactive dopamine metabolites within the striatum, and evidence correlating their reduction with clinical and pathologic measures,\textsuperscript{16-18} make F-dopa PET a potential surrogate outcome for treatment assessment. In the REAL PET trial, \textsuperscript{2} years after starting treatment, a 13% decline in F-dopa uptake was seen in the ropinirole group compared with a 20% decline in the levodopa group.\textsuperscript{19} However, patients treated with levodopa had significantly greater functional improvement and fewer side effects (excepting dyskinesia), suggesting that F-dopa PET did not meet criteria for a surrogate outcome of treatment efficacy. Additional concerns regarding the ability to utilize PET as a marker of therapeutic efficacy come from studies evaluating the safety and efficacy of fetal tissue transplantation.\textsuperscript{20-22} In these studies, a significant increase in F-dopa uptake was demonstrated in patients receiving fetal tissue transplantation. Regrettably, functional improvement was not clearly established, and a significant proportion of treated subjects in both studies developed disabling dyskinesias. This is a clear example of a case where unexpected consequences of an intervention, not detected by a potential surrogate outcome, resulted in patient harm.

The negative results of these trials have raised questions regarding the use of biomarkers in Parkinson’s disease. How can drugs affect a biomarker that suggests a slowing of disease progression in the absence of symptomatic benefits? How should symptomatic benefits in the absence of disease-modifying effects be weighed against modest neuroprotective effects in the absence of symptomatic benefits? Are biomarkers any better than clinical measures?

Some of these questions are being addressed in neuroprotective trials for Parkinson’s disease. The rationale for these trials relies on the fact that in vitro and in vivo studies have established that there is abnormal oxidative stress in Parkinson’s disease.\textsuperscript{23-25} The link between this particular disease mechanism and the clinical symptoms of the illness, however, is weak, and the goal of the trial is to detect no change in clinical status; even a worsening in clinical status could be considered a success if the rate of worsening is slower than expected. On the other hand, an improvement in clinical status is considered as a potential confounding factor since it may not relate to the neuroprotective potency of the drug but, for instance, to direct effects on the synaptic transmission. This is illustrated by the DATATOP study,\textsuperscript{26} a trial designed with the hypothesis that deprenyl, a monoamine oxidase B inhibitor, the antioxidant \(\alpha\)-tocopherol, and the combination of the two compounds, might slow the clinical progression of the disease. The results showed that patients on deprenyl were found to be less likely to require dopaminergic therapy over time, a finding that could be interpreted as evidence of a neuroprotective effect in cases of unaltered clinical status. However, the reason for the difference was that deprenyl produced a small but statistically significant symptomatic benefit, casting doubts about its neuroprotective effect.\textsuperscript{27} Accordingly, the DATATOP study demonstrates that, in trials assessing the effects of a neuroprotective drug, clinical measures cannot be considered as a gold standard for measuring disease progression. In this particular case, a biomarker directly reflecting disease progression could be substituted for a clinical measure of progression.

Psychiatry: affective disorder and schizophrenia

Clinical outcome measures in psychiatry provide several challenges for drug developers. Periods of several weeks or longer can be necessary to detect a response. Often, assessments are obtained from rating scales, which are based on psychometric, rather than pathophysiological, principles. Moreover, placebo response rates are high for many indications. Surrogate measures be applied to overcome these difficulties, but research in this field is still in its infancy. One may acknowledge that, compared with some neurological diseases such as Parkinson’s disease, illness-specific biomarkers are more poorly defined in psychiatry. In this context, defining surrogate treatment outcomes in psychiatry is premature to say the least. At the present time, only a few biomarkers have been proposed as surrogate outcomes for screening of new drugs in early clinical phases. Accordingly, this discussion is focused on biomarkers of potential interest.

Affective disorder

Affective disorder is characterized by episodes of depression and in some cases, of mania, that recur and remit repeatedly and cause shifts in a person’s mood, energy,
and ability to function. In the most severe form of affective disorder, ie, bipolar disorder, patients experience cycling of moods that usually swing from being overly elated or irritable to sad and hopeless and then back again, with periods of normal mood in between. Unequivocally validated biomarkers for affective disorder are sparse; there are, however, studies suggesting that measurement of stress hormone regulation processes, of rapid eye movement (REM) sleep or of functional magnetic resonance imaging (fMRI) activation of limbic areas could represent valuable surrogate outcome of pharmacological antidepressant activity. Stress-related dysfunctional neuroendocrine regulation implicating the corticotropin-releasing hormone (CRH) system has been consistently demonstrated in major depression, and it has been proposed that neuroendocrine dynamic challenge tests such as the combined dex/CRH test serve as a screening tool to demonstrate the antidepressive effects of new compounds in clinical drug trials. Indices of REM sleep disinhibition, such as shortened latency to REM sleep and increased density of ocular movement during REM sleep, have been proposed as a familial sleep biomarker for increased risk of developing depression. Indeed, many studies, recently reviewed, suggest that REM sleep disinhibition could reflect a dysfunction of the monoaminergic system involved in the pathophysiology of affective disorder. Drugs increasing noradrenergic or serotoninergic functions inhibit REM sleep, a property shared by most antidepressant drugs. Consequently, REM sleep inhibition has been proposed as a potential biomarker of the antidepressant activity of a compound. Dysfunction of the prefrontal cortex, including the ventral anterior cingulate gyrus, has been implicated in anhedonia, exaggerated response to stress, abnormal response after presentation of mood-lowering stimuli, serotoninergic challenges (such as tryptophan depletion paradigms), or selective serotonin reuptake inhibitor (SSRI) administration (reviewed by Hassler et al). Changes in anterior cingulate function during affective facial processing associated with symptomatic improvement indicate that such an fMRI activation paradigm may be a useful surrogate outcome of antidepressant treatment response. Another area of interest whose dysfunctional activation could serve as a surrogate outcome of antidepressant activity is the amygdala. Affective disorders have been characterized by an increased basal metabolism of the amygdala that seems to relate to hypercortisolism and REM sleep abnormalities. Increased amygdala reactivity in response to fearful stimuli has been observed in healthy individuals with a susceptibility to affective disorders. Moreover, a recent study in healthy volunteers showed that antidepressant administration decreases amygdala responses to the presentation of fearful stimuli. This indicates that the amygdala response to fearful stimuli, even in healthy subjects, could represent a surrogate outcome of the pharmacological effects of antidepressants.

Schizophrenia

Schizophrenia is a chronic psychiatric illness manifested by characteristic and severe distortions of thinking and perception, and by inappropriate or blunted affect. Symptoms of schizophrenia may be divided into positive symptoms (including hallucinations, delusions, and disorganized speech and behavior), negative symptoms (including a decrease in emotional range, poverty of speech, loss of interests, and loss of drive) and cognitive symptoms (including deficits in attention and executive functions such as organizational ability and abstract thinking). The diagnosis is made from a pattern of signs and symptoms, in conjunction with impaired occupational or social functioning. As for affective disorder, there are, at the present time, no surrogate treatment outcomes for schizophrenia. Some biomarkers have been proposed as tools for the development of new antipsychotic drugs, and will be further discussed. Abnormal evoked response electronecephalography (EEG) potentials have been shown to characterize patients with schizophrenia, and are suggested to reflect disturbances of neuropsychological functioning. In this model, it is believed that schizophrenia patients are overwhelmed by sensory input that they have trouble organizing, due to a deficit in the filtering or the gating process of extraneous sensory stimuli. Among the several methods that have been used to investigate this putative deficit in inhibitory neuronal processing, we will focus on the two most widely used techniques, P50 auditory sensory gating and the prepulse inhibition of the acoustic startle response. Abnormal P50 and prepulse inhibition responses have been observed in patients with schizophrenia and in their families. The P50 is a small-amplitude, positive event-related potential that occurs about 50 msec after an auditory stimulus. Repeated pairs of clicks, separated by about 500 msec, typically elicit an initial excitatory response followed by a diminished response, because the inhibitory
mechanism activated by the first stimulus interferes with the excitatory response to the second stimulus. The percentage reduction in the amplitude of the P50 response from the first to the second click is the dependent variable labeled “P50 suppression.” Significantly lower suppression is found in schizophrenia patients.44-47 Interestingly, treatment with clozapine, but not with conventional antipsychotic drugs such as haloperidol, reverses this deficit.48 Moreover, subsequent studies have shown that other atypical antipsychotic medication did not share this property with clozapine49 and that improvement in P50 sensory gating was a predictor of clozapine response in schizophrenia patients.50 These findings suggest that P50 could be a valuable biomarker for the development of new antipsychotic agents, given the fact that clozapine is clinically more effective in a significant proportion of schizophrenic patients refractory to other drug treatment.

Another auditory electrophysiological parameter assessing sensorimotor gating is the prepulse inhibition of the acoustic startle response. It refers to the ability of a weak (prepulse) stimulus to transiently inhibit the reflex response to a closely following stronger (pulse) stimulus. Prepulse inhibition deficits have been observed in patients with schizophrenia44,45 including in drug-naive patients.51,52 In rats, prepulse inhibition is disrupted by systemic administration of dopamine agonists, serotonin agonists, or glutamate antagonists, and this paradigm has been proposed as an animal model for predicting antipsychotic activity of novel compounds.53 As for P50 suppression, there is preliminary evidence suggesting that, in contrast to other antipsychotic drugs including atypical antipsychotics, clozapine treatment improves the prepulse inhibition deficits of schizophrenic patients.54 This indicates that indices of sensorimotor gating deficit measured by either P50 or prepulse inhibition paradigms are interesting biomarkers for the development of new clozapine-like antipsychotic drugs.

Conclusions

At this time, the significance of surrogate markers of treatment outcome in neurology and psychiatry is not yet sufficiently understood; moreover, no surrogate markers have been validated to be used as a sole primary measure of effectiveness in trials of investigational drugs. Although unvalidated (in the sense described earlier) surrogate outcomes have been successfully used for anticancer or anti-AIDS drugs, a sponsor who wishes to obtain approval on the basis of the effect of a drug on such an unvalidated marker will need to adequately demonstrate that any such effect will be “reasonably likely” to predict the desired clinical effect. Evidence supporting this remains to be found. It may include both animal and human data, and requires further investigation into the pathophysiology of the condition under study and into the pharmacology of the drug under study.

REFERENCES

1. Biomarkers Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharm Ther. 2001;69:89-95.
2. Woodcock J. Presentation of FDA Document, Draft Guidance for Industry: Pharmacogenomic Data Submission. 13 November 2003. (See section 506(b) of the Act [21 U.S.C. sec.356]; see also Guidance for Industry: Fast Track Drug Development Programs—Designation, Development, and Application Review, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research [September 1998] at 2 ["Section 506(b) essentially codifies in statute FDA’s accelerated approval regulations."]).
3. Barry MJ. PSA screening for prostate cancer: the current controversy—a viewpoint. Patient Outcomes Research Team for Prostatic Diseases. Ann Oncol. 1998;9:1279-1282.
4. Bunting PS. Screening for prostate cancer with prostate-specific antigen: beware the biases. Clin Chim Acta. 2002;315:71-97.
5. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol. 2003;21:1404-1411.
6. Bucher HC, Guyatt GH, Cook DJ, Holbrook A, McAlister FA. Users’ guides to the medical literature. XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. JAMA. 1999;282:771-778.
7. Fleming TR. Surrogate endpoints and FDA’s accelerated approval process. Health Affairs. 2005;24:67-78.
8. Burn DJ, Sawle GV, Brooks DJ. Differential diagnosis of Parkinson’s disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J Neurol Neurosurg Psychiatry. 1994;57:278-284.
9. Marek K, Innis R, van Dyck C, et al. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression. Neurology. 2001;57:2089-2094.
10. Marek K, Jennings D, Seibyl J. Single-photon emission tomography and dopamine transporter imaging in Parkinson’s disease. Adv Neurol. 2003;91:183-191.
11. Parkinson Study Group. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in Parkinsonism. Mov Disord. 2001;16:7-78.
Mediciones sustitutas en neurología, psiquiatría y psicofarmacología

Una medición sustituta se puede definir como un parámetro (marcador) mensurable en forma precoz, a menor costo y de manera menos invasora que el parámetro real; y que permite inferencias válidas acerca del efecto de la intervención en el parámetro real. Existe un creciente interés en el empleo de mediciones sustitutas de la eficacia terapéutica en investigación de ensayos de fármacos. Sin embargo, el significado de mediciones sustitutas de eficacia terapéutica en neurología y psiquiatría aun no ha sido suficientemente demostrado. De hecho, pocos de estos marcadores han sido adecuadamente “validados,” es decir, que hayan mostrado su valor predictor en relación al efecto clínico de un determinado tratamiento. En este artículo se discute la evidencia que podría sustentar la validación de tales marcadores. Los biomarcadores empleados durante los programas de desarrollo iniciales de nuevos fármacos psicotrópicos son considerados en el contexto de la enfermedad de Parkinson, los trastornos afectivos y la esquizofrenia. El caso particular de los ensayos de moléculas neuroprotectoras está ejemplificado en la enfermedad de Parkinson, donde un biomarcador sustituto para la medición clínica de la progresión de la enfermedad podría considerarse como una medición sustituta de la eficacia del tratamiento.

13. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA. 2000;284:1931-1938.
14. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson’s disease progression. JAMA. 2002;287:1653-1661.
15. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2005;351:2498-2508.
16. Vingerhoets FJ, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol. 1994;36:759-764.
17. Snow BJ, Tooyama I, McGeer EG, et al: Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol. 1993;34:324-330.
18. Ribeiro MJ, Vidalhiet M, Loch C, et al. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson’s disease. Arch Neurol. 2002;59:580-586.
19. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003;54:93-101.
20. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med. 2001;344:710-719.
21. Olason CW, Kieburz K, Stern M, et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol. 2004;61:1563-1568.
22. Hagell P, Cenci MA. Dyskinesias and dopamine cell replacement in Parkinson’s disease: a clinical perspective. Brain Res Bull. 2005;68:4-15.
23. Zhang Y, Dawson VL, Dawson TM. Oxidative stress and genetics in the pathogenesis of Parkinson’s disease. Neurobiol Dis. 2000;7:240-250.
24. Youdim MB, Grunblatt E, Levites-Royak Y, Mandel S. Drugs to prevent cell death in Parkinson’s disease. Neuroprotection against oxidative stress and inflammatory gene expression. Adv Neurol. 2001;86:115-124.
25. Schapira AH. Disease modification in Parkinson’s disease. Lancet Neurol. 2004;3:362-368.
26. Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson’s disease. Arch Neurol. 1989;46:1052-1060.
27. Landau WM. Clinical neuromyology IX. Pyramid sale in the bucket shop: DATATOP bottoms out. Neurology. 1990;40:1337-1339.
Clinical research

28. Holsboer F. The corticosteroid receptor hypothesis of depression. *Neuropsychopharmacology*. 2000;23:477-501.

29. Müller MB, Wurst W. Getting closer to affective disorders: the role of the CRH receptor system. *Trends Mol Med*. 2004;10:409-415.

30. Duval F, Mokrani MC, Ortiz JA, Schulz P, Champeval C, Machet JP. Neuroendocrine predictors of the evolution of depression. *Dialogues Clin Neurosci*. 2005;7:273-282.

31. Ising M, Kunzel HE, Binder EB, Nickell T, Modell S, Holsboer F. The combined dexamethasone/CRH test as a potential surrogate marker in depression. *Prog Neuropsychopharmacol Biol Psychiatry*. 2005;29:1085-1093.

32. Modell S, Ising M, Holsboer F, Lauer C. The Munich vulnerability study on affective disorders: premorbid polysomnographic profile of affected high-risk probands. *Biol Psychiatry*. 2005;58:694-699.

33. Staner L, Luthringer R, Le Bon O. Sleep disturbances in affective disorders. In: Pandi-Perumal SR, Monti JM, eds. *Clinical Pharmacology of Sleep*, Basel, Switzerland: Birkhäuser Verlag; 2006:101-124.

34. Dumont GJ, de Visser SJ, Cohen AF, van Gerven JM. Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects. *Br J Clin Pharmacol*. 2005;59:495-510.

35. Staner L, Luthringer R, Machet JP. Effects of antidepressant drugs on sleep EEG in patients with major depression. Mechanisms and therapeutic implications. *CNS Drugs*. 1999;11:49-60.

36. Hassler G, Drevets W, Manji H, Charney D. Discovering major endophenotypes for major depression. *Neuropsychopharmacology*. 2004;29:1765-1781.

37. Fu CH, Williams SC, Cleare AJ, et al. Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. *Arch Gen Psychiatry*. 2004;61:877-889.

38. Charney MS, Drevets WC. The neurobiological basis of anxiety disorders. In: Davis KL, Charney DS, Coyle JT, Nemeroff CB, eds. *Neuropsychopharmacology: the Fifth Generation of Progress*, Philadelphia, PA: Lippincott Williams & Wilkins; 2002:901-930.

39. Hariri AR, Mattay VS, Tessitore A, et al. Serotonin transporter genetic variation and the response of the human amygdala. *Science*. 2002;297:400-403.

40. Hariri AR, Drabant EM, Munoz KE, et al. A susceptibility gene for affective disorders and the response of the human amygdala. *Arch Gen Psychiatry*. 2005;62:146-152.

41. Heinz A, Braus DF, Smolka MN, et al. Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter. *Nat Neurosci*. 2005;8:20-21.

42. Harmer CJ, Mackay CE, Reid CB, Cowen PJ, Goodwin GM. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. *Biol Psychiatry*. 2006 Feb 3;[Epub ahead of print].

43. Swerdlow NR, Koob GF. Dopamine, schizophrenia, mania, and depression: toward a unified hypothesis of cortico-striato-pallido-thalamic function. *Behav Brain Sci*. 1987;10:197-245.

44. Braff DL, Geyer MA. Sensorimotor gating and schizophrenia. Human and animal studies. *Arch Gen Psychiatry*. 1990;47:181-188.

45. Light GA, Braff DL. Human and animal studies of schizophrenia-related gating deficits. *Curr Psychiatry Rep*. 1999;1:31-40.

46. Siegel C, Waldo M, Mizner G, Adler LE, Freedman R. Deficits in sensory gating in schizophrenic patients and their relatives. Evidence obtained with auditory evoked responses. *Arch Gen Psychiatry*. 1984;41:607-612.

47. Boutros NN, Zouridakis G, Overall J. Replication and extension of P50 findings in schizophrenia. *Clin Electroencephalogr*. 1991;22:40-46.

48. Nagamoto HT, Adler LE, Hea RA, Griffith JM, McRae KA, Freedman R. Gating of auditory P50 in schizophrenics: unique effects of clozapine. *Biol Psychiatry*. 1996;40:181-188.

49. Adler LE, Olincy A, Cawthra EM, et al. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. *Am J Psychiatry*. 2004;161:1822-1828.

50. Chung C, Remington G. Predictors and markers of clozapine response. *Psychopharmacology*. 2005;179:317-335.

51. Mackeprang T, Kristiansen KT, Glenthoj BY. Effects of antipsychotics on prepulse inhibition of the startle response in drug-naive schizophrenic patients. *Biol Psychiatry*. 2002;52:863-873.

52. Ludewig K, Geyer MA, Vollenweider FX. Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia. *Biol Psychiatry*. 2003;54:121-128.

53. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. *Psychopharmacology*. 2001;156:117-154.

54. Oranje B, Van Oel C, Gispen-De Wied CC, Verbanen MN, Kahn RS. Effects of typical and atypical antipsychotics on the prepulse inhibition of the startle reflex in patients with schizophrenia. *J Clin Psychopharmacol*. 2002;22:359-365.